All About SGLT Inhibitors for T1D

SGLT inhibitors are oral medications that work by decreasing the production of transport proteins and reducing the absorption of glucose by the intestines and kidneys respectively. Up until now, these drugs have been used exclusively by those with Type 2 diabetes. Inhibitors on the market currently include SGLT-2 inhibitors Farxiga and Jardiance, and Zynquista, the first dual SGLT-1 and SGLT-2 inhibitor.

Disparities in Diabetes and Diabetes Care—What Can We Do About It?

At this ADA 2020 session, systemic racism and implicit bias were clear contributors to poor health and healthcare outcomes for Black and Latinx communities.

T1D Exchange + Beyond Type 1 Marathon Study Presented at ADA 2020

The Beyond Type Run team has taken on 26.2 miles to not only raise awareness and funds for T1D, but to provide crucial data for a study pertaining to management of Type 1 before, during, and after a marathon.

Medicare Part D Senior Savings Model Caps Insulin Costs at $35 per Month

The Senior Savings Model caps out of pocket insulin costs at $35 per month for seniors enrolled in eligible plans.

England’s NHS Releases Study on Risk of COVID-19 for People with Diabetes

This week, the National Health Service (NHS) in England released the first study of its kind, breaking down COVID-19 mortality risk by type of diabetes.

Armed For Diabetes Created to Help Veterans With Resources For Better Diabetes Management

Armed for Diabetes highlights continuous glucose monitoring prescribing guidelines for veterans.

DreaMed Announces Virtual Clinic to Treat T1D During COVID-19

On April 21, DreaMed Diabetes announced the inception of a virtual diabetes clinic to treat those with Type 1 diabetes remotely over the course of the COVID-19 pandemic.

Minnesota Passes the Alec Smith Insulin Affordability Act

The Alec Smith Insulin Affordability Act was signed into law in Minnesota, providing MN residents options for emergency and ongoing insulin access for those who qualify.

FreeStyle Libre Approved by FDA for Hospitalized Patients During COVID-19 Pandemic

Abbott's FreeStyle Libre 14 day system will allow doctors to remotely monitor their patient's glucose levels.

Senseonics Suspends Commercial US Sales of Eversense in Response to COVID-19

On March 26, Senseonics suspended all commercial sales of the Eversense continuous glucose monitor (CGM) in the United States.

Beyond Type 1 Supports Smarter Healthcare Coalition (SHCC) in Urging Congress to Expand Telehealth Coverage

On March 20, Beyond Type 1 signed a letter to Congress penned by the Smarter Healthcare Coalition, urging the broadening of telehealth coverage for COVID-19.

Dexcom G7 Updates with CEO Kevin Sayer

Dexcom CEO Kevin Sayer discusses Dexcom’s international strategy, the next-generation Dexcom G7, and the response to the Dexcom Follow outage last Fall.

The Diabetes Disaster Response Coalition Coronavirus Response

On March 12, the Diabetes Disaster Response Coalition (DDRC) circulated an update to coalition members in response to coronavirus (COVID-19). Here are the steps the organization is taking and other important information to note.

New Medicare Plan Will Cap Insulin Copays at $35

On March 11, the Centers for Medicare & Medicaid Services (CMS) launched a new plan for some Medicare Part D participants to pay a maximum $35 copay for their monthly supply of insulin.

Omnipod Closed Loop Technology to be Compatible with both Abbott and Dexcom CGMs

Abbott and Dexcom announced formal partnerships with Insulet to be compatible as CGMs on the Omnipod Horizon Automated Insulin Delivery System.